

SI Fig 1 **Tumor growth in rats treated with non-reduced tumor lysate *versus* control (Adjuvant only) in two separate experiments**

For this experiment rat tumor lysate was prepared as follows. 1ml rat lysate was precipitated overnight at -20°C with 10ml acetone followed by centrifugation at 12,100g for 30 mins at 4°C. The pellet was allowed to dry before being resuspended in 400 µl sterile phosphate buffered saline (PBS). This was mixed with 400 µl Freund's Incomplete Adjuvant (FIA; Sigma, St Louis, Missouri, USA) and provided non-reduced vaccine for 3 rats. Rats received 250 µl of vaccine or FIA in PBS (controls) intraperitoneally (i.p), followed by a booster shot 3 weeks later. Rats were then challenged with $1x10^6$ 9L cells in 100 µl serum free media in the flank and this was termed day zero. Tumors were measured by calipers 3 times per week and tumour volume calculated using the equation $(width^2 \times length)/2 = cm^3$.
The horizontal line indicates a tumor volume of $13.5cm^3$ (approximately 3 cm by 3 cm) and the ethical endpoint for euthanasia.



SI Fig 2

A. Interferon-γ levels in controls, single vaccine dose or 2 dose treated rats 21 days post tumour challenge.
B. IL-4 levels in controls, single vaccine dose or 2 dose treated rats 21 days post tumour treatment.

* = $p < 0.05$



SI Fig 3

A. Vaccine (50) versus control (adjuvant only) in a repeat experiment. Vaccine (50) rats received 2 s.c doses of vaccine 3 weeks apart. Rats (n=3 for each group) were challenged with $1x10^6$ 9L cells in 100 µl serum free media in the flank at day zero.

B. Low dose streptavidin vaccine experiment. Rats received 2 s.c doses of vaccine at either 2.5 µg, 20µg or 50µg streptavidin per dose three weeks apart. Rats were then challenged with $1x10^6$ 9L cells in 100 µl serum free media in the flank and this was termed day zero (n=3 for each group).



SI Fig 4

A. C-reactive protein levels post vaccination/pre-tumour challenge and 21 days post tumour challenge.
B. CINC-1 serum levels at endpoint

* = $p < 0.05$



SI Fig 5 **Survival of rats vaccinated with vaccine produced using the canine vaccine production method versus control (adjuvant only)**



SI Fig 6

A. Silver stain of a typical canine Individualized autologous vaccine
B. Streptavidin binding in canine autologous vaccine
C. Biotin binding in canine autologous vaccine.
D. Silver stain of rat glioma vaccine (50)
E. Streptavidin binding in a glioma vaccine (50)
F. Biotin binding in glioma vaccine (50).

Std: Standard molecular weight marker (Precision plus Biorad)